CDC-RFA-DP-24-0059: Mississippi Delta Health Collaborative
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of Centers for Disease Control - NCCDPHP notices from 2024.
Centers for Disease Control - NCCDPHP offered grants of up to $3.1 million (at least $3.1 million) to the applicants described in the notice. It expected to make one award worth $15.8 million in total. Applications closed on June 24, 2024.
From the official notice on Grants.gov, last changed June 20, 2024. Checked November 7, 2026.
- Award ceiling$3.1 million
- Award floor$3.1 million
- Total funding$15.8 million
- Expected awards1
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | April 18, 2024 |
|---|---|
| Deadline | June 24, 2024 |
| Archived by Grants.gov | July 24, 2024 |
Who can apply
This opportunity was open to the applicants described in the notice.
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Financial assistance from this Notice of Funding Opportunity will be provided only to the Mississippi Department of Health /Mississippi Delta Health Collaborative (MDHC). No other applications will be solicited or reviewed.
Is this a realistic fit?
- Past Preventing Heart Attacks and Strokes in High Need Areas awards averaged $9.3 million; this notice allows up to $3.1 million per award.
- Most of the program's money (100% over five years) went to state and local governments.
- No cost sharing or match is required.
What the grant funds
The Mississippi Delta is a historically and culturally rich region of the United States. The architecture, French, Spanish, British, and German, is as diverse as the people whose origins are European, Native American, Spanish, African, and more. But for all its cultural wealth, there is a poverty of health and healthcare in the region. Residents of the 18-county region contend with persistent poor health outcomes compounded by challenges to attaining preventive services and care, poor quality of care, and stagnant opportunity structures, particularly as it relates to cardiovascular disease (CVD).Roughly 1 in 10 (9.9% ≈ 28.6 million) adults in the US have at least 1 type of CVD, including coronary heart disease, heart failure, or stroke. This number excludes hypertension, a risk factor for and cause of CVD but not a type of CVD. However, hypertension or high blood pressure is a critical risk factor for stroke. An estimated 120 million American adults (48.1%) have it, most (3 in 4) don’t have it controlled, and 1 in 5 adults is unaware they have hypertension. In 2012 CVD, particularly heart disease, was the leading cause of death in the Delta (244.4 deaths per 100,000). The region’s residents experience age-adjusted death rates due to heart disease, stroke, and other CVDs that are considerably higher than national rates and the rest of Mississippi. According to the 2018 Cardiovascular Health Examination Survey (CHES) in the Mississippi Delta, the adjusted overall prevalence of hypertension among adults in the region 18 and older was 42.8%.The persistence of these outcomes in the Delta is attributable to modifiable CVD conditions and risk factors, such as high blood pressure, high cholesterol, coronary heart disease, COPD, chronic kidney disease, diabetes, and stroke. To sufficiently address these conditions, interventions must include evidence-based and practice-based approaches that are innovative and tailored to the unique challenges and strengths of the 18-county MS Delta Region. These interventions are needed in strategies that are focused on health systems, team-based care, and linkages to community resources and clinical services that address the social conditions that contribute to the prevalence of CVD in the MS Delta Region. This cooperative agreement builds from lessons learned from previous iterations.
Who has won Preventing Heart Attacks and Strokes in High Need Areas grants before
From fiscal 2021 to 2025, Preventing Heart Attacks and Strokes in High Need Areas (93.816) awarded $9.3 million across 1 grant award, an average of $9.3 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Mississippi State Department of Health | Mississippi | 1 | $9.3 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is CDC-RFA-DP-24-0059 still open?
No. It closed on June 24, 2024.
Who can apply for Mississippi Delta Health Collaborative?
Centers for Disease Control - NCCDPHP accepted applications from the applicants described in the notice. The notice adds further conditions, so read its eligibility section.
What is the deadline for Mississippi Delta Health Collaborative?
Closed June 24, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $3.1 million each. About $15.8 million in total for one award.
Who has won Preventing Heart Attacks and Strokes in High Need Areas grants before?
The largest recipients over five fiscal years were Mississippi State Department of Health. The program made 1 awards worth $9.3 million in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)